10/31/2013

The Leukemia & Lymphoma Society is partnering with Stemline Therapeutics to support the development of the experimental drug SL-401 for the treatment of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The Leukemia & Lymphoma Society pledged more than $3 million for the project and will work to increase the awareness of physicians and patients about blastic plasmacytoid dendritic cell neoplasm.

Related Summaries